Amicus Therapeutics Inc (NASDAQ:FOLD)

15.17
Delayed Data
As of Feb 16
 -0.66 / -4.17%
Today’s Change
5.87
Today|||52-Week Range
17.40
+5.42%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.5B

Company Description

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Contact Information

Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury New Jersey 08512
P:(609) 662-2000
Investor Relations:
(609) 662-5000

Employees

Shareholders

Other institutional71.34%
Mutual fund holders52.20%
Individual stakeholders37.16%

Top Executives

John Francis CrowleyChairman & Chief Executive Officer
Bradley L. CampbellPresident & Chief Operating Officer
Chip BairdChief Financial Officer
Enrique DiloneSenior Vice President-Technical Operations
Jay A. BarthChief Medical Officer